玻璃体腔注射康柏西普治疗主干型及黄斑型视网膜分支静脉阻塞临床对比观察被引量：3

在线阅读下载PDF

导出

摘要目的对比观察玻璃体腔注射康柏西普治疗主干型及黄斑型视网膜分支静脉阻塞(BRVO)的疗效。方法BRVO患者43例,根据FFA检查结果分为主干型BRVO组(24例)及黄斑分支型BRVO组(19例),两组患者均接受玻璃体腔注射康柏西普治疗,并随访6个月,观察两组患者治疗前(T0)及治疗后6个月时(T1)最佳矫正视力(BCVA)、黄斑中心凹视网膜厚度(CFT)、黄斑区6 mm直径视网膜体积、黄斑中心凹下脉络膜厚度、视网膜出血相对面积,观察随访期内重复给药次数及并发症。结果两组患者T1时BCVA、CFT、黄斑区6 mm直径视网膜体积、黄斑中心凹下脉络膜厚度、视网膜出血相对面积,与T0时相比均降低(P均<0.05);主干型BRVO组患者T1时BCVA、CFT、黄斑区6 mm直径视网膜体积均低于黄斑分支型BRVO组患者(P均<0.05);主干型BRVO组患者T0时视网膜出血相对面积高于黄斑分支型BRVO组患者(P<0.05)。随访期内,27例患者接受重复给药,主干型BRVO组患者19例、黄斑分支型BRVO组患者8例,两组相比,P<0.05;重复给药患者中主干型BRVO组平均接受玻璃体腔内注射康柏西普(2.89±0.74)次,黄斑分支型BRVO组(2.25±0.46)次,两组相比,P<0.05;6例患者发生一过性眼压增高,主干型BRVO组患者3例、黄斑分支型BRVO组患者3例,两组相比,P>0.05。结论经玻璃体腔注射康柏西普治疗后,黄斑分支型BRVO患者视力提高程度、CFT、黄斑区6 mm直径视网膜体积下降幅度均优于主干型BRVO患者,并且重复给药次数更少。

作者尹世达宋丽华刘敏刘英陶远王红

机构地区山东大学齐鲁医院东营市东营区人民医院济南市第八人民医院山东省荣军总医院济南市第二人民医院

出处《山东医药》 CAS 2019年第36期79-81,共3页 Shandong Medical Journal

关键词视网膜分支静脉阻塞主干型视网膜分支静脉阻塞黄斑分支型视网膜分支静脉阻塞康柏西普血管内皮生长因子玻璃体腔注射

分类号 R774 [医药卫生—眼科]

作者简介通信作者:王红(E-mail:dr.wanghong@163.com)。

引文网络
相关文献

参考文献1

1孟,魏文斌,李燕龙,韩晓冬.玻璃体腔注射雷珠单抗治疗病理性近视脉络膜新生血管的疗效观察[J].中华眼底病杂志,2016,32(1):70-72. 被引量：12

二级参考文献16

1Blinder KJ,Blumenkranz MS,Bressler NM,et al.Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia:2-year results of a randomized clinical trial-VIP report no.3[J].Ophthalmology,2003,110(4):667-673.
2Brown DM,Michels M,Kaiser P,et al,Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration:two-year results of the ANCHOR study [J].Ophthalmology,2009,116(I);57-65.DOI:10.1016/j. Ophtha.2008.10.018.
3Tufail A,Patel PJ,Sivaprasad S,et al.Ranibuzumab for treatment of choroidal neovascularization secondary to pathological myopia,interim analysis of REPAIR study[J].Eye (Lond),2013,27(6):709-715.DOI:10.1038/eye.2013.8.
4Tong JP,Chan WM,Liu DT,et al.Aqueous humor levels of vascular endothelial growth factor and pigment epithelium- derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization[J].Am J Ophthalmol,2006,141(3):456-462.DOI:10.1016/j.ajo.2005,10.012.
5Ciulla TA,Rosenfeld PJ.Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration[J]. Curr Opin Ophthalmol,2009,20(3):158-165.DOI;10.1097/ ICU.0b013e32832d25b3.
6Lai TY,Chan WM,Liu DT,et al.Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia[J].Retina,2009,29:750-756.DOI;10.1097/IAE.0b013e318l9ed6bd.
7Calvo-Gonzalez C,Reche-Frutos J,Donate J,et al.Intravitreal ranibizumab for myopic choroidal neovascularization:factors predictive of visual outcome and needfor retreatment[J].Am J 0phthalmol,2011,151(3):529-534.DOI:10.1016/j.ajo.2010.09.021.
8Mones JM,Amselem L,Serrano A,et al.Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia:12-month results[J].Eye ( Lond), 2009,23(6):1275-1280. DOI:10.1038/eye.2009.88.
9Silva RM,Ruiz-Moreno JM,Nascimento J,et al.Short-term efficacy and safety of intravitreal ranibizumab for myopic choroida lneovascularization[J],Retina,2008,28(8):1117-1123.DOI:10.1097/IAE.0b013e31817eda41.
10Konstantinidis L,Mantel I,Pournaras JA,et al.Intravitreal ranibizumab(Lucentis)for the treatment of myopic choroidal neovascularization[J].Graefey s Arch Clin Exp Ophthalmol, 2009,247(3):311-318.DOI:10.1007/s00417-008-0995-0.